Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferrous succinate for prevention of VCI after stroke
NCT03891277Phase 2Unknown
- Sponsor
- Beijing Tiantan Hospital
- Start
- Apr 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ferrous succinate in vascular cognitive impairment (VCI), sponsored by Beijing Tiantan Hospital. Primary endpoint: Prevalence of Vascular Cognitive Impairment at 1 year. Status: unknown.
02
Drugs
ferrous succinate
03
Conditions
vascular cognitive impairment (VCI)
Beyond the preview
Go deeper on NCT03891277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03891277.